A randomized, open-label, single-dose study to evaluate the safety and pharmacokinetics of two formulations containing 40 mg of fexuprazan in healthy Korean subjects [0.03%]
fexpaz口服单次给药在健康韩国受试者中的随机、开放标签I期研究：两种片剂规格（40毫克）的耐受性和药代动力学比较
Joon Hur,Jin A Lee,Hyung Park et al.
Joon Hur et al.
Objective: To evaluate the pharmacokinetics and safety of two 40-mg fexuprazan formulations. Materials and methods: This study was an o...
Low-dose lamotrigine co-administration decreases quetiapine plasma concentrations: Effect of UGT2B7-161C>T polymorphism in Japanese patients with depression [0.03%]
小剂量拉莫三嗪联合给药可降低喹硫平的血浆浓度：在日本抑郁患者中的UGT2B7-161C>T多态性的影响
Takeshi Suzuki,Goyo Nagai,Kazuo Mihara et al.
Takeshi Suzuki et al.
Objectives: Previous findings showing that lamotrigine co-administration decreases serum quetiapine concentrations were based solely on group comparisons using therapeutic drug monitoring databases. The present prospectiv...
Adenosine-2A agonists: Positioning as functional contrast agents in diagnostic cardiology [0.03%]
腺苷2A受体激动剂：作为功能对比剂在诊断心脏病学中的定位研究
Barrington G Woodcock-Kloberdanz
Barrington G Woodcock-Kloberdanz
Hemoglobin A1c levels in patients with type 2 diabetes mellitus receiving oral semaglutide with versus without proton pump inhibitors: An exploratory study [0.03%]
口服塞马鲁肽联合质子泵抑制剂与单纯口服塞马鲁肽治疗2型糖尿病患者对血红蛋白A1c水平影响的探索性研究
Satoru Matsunuma,Yusuke Hirota,Koichi Yoshimoto
Satoru Matsunuma
Objective: Oral semaglutide contains salcaprozate sodium, which promotes the opening of epithelial tight junctions and increases gastric pH to prevent its degradation; these actions together improve absorption. Proton pum...
Epidemiological characteristics of severe skin adverse reactions caused by immune checkpoint inhibitors based on case reports [0.03%]
基于个案报告的免疫检查点抑制剂所致重度皮肤不良反应的流行特征分析
Su-Na Tang,Xiao-Wen Ma,Xiao-Yan Zhang et al.
Su-Na Tang et al.
Objective: To investigate the epidemiological characteristics of severe cutaneous adverse reactions (cirAEs) induced by immune checkpoint inhibitors (ICIs) and to provide evidence for the rational clinical use of ICIs and...
Pharmacokinetics and safety of a telmisartan/amlodipine/rosuvastatin fixed-dose combination tablet compared to co-administration of telmisartan/amlodipine and rosuvastatin in healthy Korean male volunteers [0.03%]
telmisartan/氨氯地平/罗苏伐他汀复方制剂与分别服用telmisartan/氨氯地平及罗苏伐他汀在健康中国男性受试者中的药代动力学和安全性比较研究
Seol Ju Moon,Jeong-Soo Park,Yong-Geun Kwak et al.
Seol Ju Moon et al.
Objective: This study was conducted to compare the single-dose pharmacokinetic and safety profiles of JLP-1401 (fixed-dose combination (FDC) of telmisartan/amlodipine/rosuvastatin) to those of each constituent co-administ...
Pharmacokinetics of the potassium-competitive acid blocker tegoprazan administered by the oral route in healthy Mexicans [0.03%]
口服替加奥扎ン在健康墨西哥人中的药代动力学（钾竞争性酸阻滞剂）
Miriam Del Carmen Carrasco-Portugal,Gisselle Vanessa González-Hernández,Pablo David López-Cartagena et al.
Miriam Del Carmen Carrasco-Portugal et al.
Background: Tegoprazan is a potassium channel inhibitor with an anti-acid secretion effect. It is metabolized by CYP3A4, a cytochrome enzyme the occurrence of which in the Mexican population, differs from that in some oth...
Effect of AST-120 treatment discontinuation and serum albumin on free and bound indoxyl sulphate in end-stage kidney disease [0.03%]
AST-120停药和血清白蛋白对终末期肾病患者游离及结合吲哚硫酸铵的影响
Takuya Yoshida,Masayuki Tsujimoto,Haruno Fujioka et al.
Takuya Yoshida et al.
Objective: To examine the effects of the oral uremic toxin absorbent AST-120 on the concentration of free and protein-bound indoxyl sulphate (IS) and to assess the effects of serum albumin in end-stage kidney disease (ESK...
Colistin-induced neurotoxicity in a young patient with multidrug-resistant Pseudomonas aeruginosa bacteremia: A case report [0.03%]
碳氢霉烯类耐药铜绿假单胞菌感染患者的复方多粘菌素B神经毒性反应病例报告
Mirna Momcilovic,Marko Siroglavic,Vedran Pasara et al.
Mirna Momcilovic et al.
Objective: To present a case of suspected colistin-induced neurotoxicity, likely resulting from drug accumulation during treatment of multidrug-resistant Pseudomonas aeruginosa (PA) bacteremia. ...